Letter to Administration: “America Falls Behind in Hepatitis Elimination Efforts”

Last Updated on May 13, 2020 by HepFree NYC
A network building capacity to prevent, manage and treat hepatitis B and C in NYC

Last Updated on May 13, 2020 by HepFree NYC
This Plan updates the Center’s current strategic plan and serves as a blueprint for achieving our vision of a future free of HIV, viral hepatitis, STDs, and TB.
DA approved revisions to the Olysio (simeprevir) label to include dosing recommendations for the treatment of HCV/HIV-1 coinfection and to expand the indications and usage to include genotype 4 infection.
Governor Andrew M. Cuomo today signed into law a bill that increases access to hepatitis C, or HCV, tests by allowing physicians and nurse practitioners to authorize registered nurses, when appropriate, to administer the test to a patient without the need for a patient-specific o...
Olysio has been approved by the FDA, in combination with Sovaldi, for the treatment of Hepatitis C. It is substantially more expensive than Harvoni; although it depends on treatment time, a 12-week Harvoni treatment costs $94,500, compared to the Olysio-Sovaldi 12-week tag of $1...
On February 6th, in our State's Capital, join hundreds of people living with Hep C, elected officials, healthcare professionals, services providers and people for a day of advocacy and action.
The Action Plan’s goals guide individuals and organizations to strengthen the response to Hep B and C.
Project INSPIRE — CMS-funded Innovations Award Summary: The NYC Department of Health has announced the receipt of a new grant from the Federal government to improve treatment for hepatitis C. The grant will allow the Health Department, in conjunction with the Fund for Public He...
An American Immigrant women’s study. You are invited to join a women’s health and safety study available in English, Spanish, French, Hmong, Arabic, Swahili and Somali. You can receive up to $40 for each completed survey; $115 for the whole year. See here for more in...